A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)

Phase 3

Recruiting

• Conditions: Venous Leg Ulcer (VLU)
• Interventions: Drug: EscharEx (EX-03); Drug: Placebo (Gel vehicle)

• Registration Number: NCT06568627
• Lead Sponsor: MediWound Ltd

Brief Summary

The main objective of this study is:

To assess the efficacy and safety of EscharEx (EX-03 5% formulation) compared to placebo control,in debridement and wound bed preparation of Venous Leg Ulcers (VLU).

Detailed Description

At least 216 eligible adult patients with VLU (with a surface area between 2 cm2 and 25 cm2, and wound age between 4 weeks and 12 months), will be randomized. The patients will be treated with IMP (either EX-03 5% or placebo) in a double blinded manner.

Total duration of the study is up to 27 weeks:

1. Screening period (2 visits, 7 days apart),

2. Daily Visits Period - Debridement with IMP (up to 8 daily site visits within up to 2 weeks),

3. Weekly Visits Period - wound management (up to 11 visits within up to 10 weeks) + optional wound closure confirmation (up to 2 weeks). Wound will be managed in a standardized manner.

4. Monthly Visits Period - Wound Closure Durability Period of 12 weeks starting after wound closure confirmation (3 visits within 12 weeks). per formed only for wound closed during weekly visits period.

Study Timeline

• Study First Submitted: 2024-08-04
• Study First Submitted QC: 2024-08-22
• Study First Posted: 2024-08-23
• Status Verified: 2025-04
• Study Start: 2025-04
• Last Update Submitted: 2025-04-21
• Last Update Posted: 2025-04-24
• Primary Completion: 2026-12
• Study Completion: 2027-03

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 216

Inclusion Criteria

1. Men or women, older than 18 years of age,
2. Patients with a VLU (determined by medical history, physical examination, and a documented ultrasound scan demonstrating venous insufficiency),
3. Wound is present for at least 4 weeks but no longer than 1 year,
4. The necrotic/slough/fibrin non-viable tissue area is at least 50% of the wound area (assessed by clinical evaluation),
5. Target wound surface area is in the range of 2-25 cm2 (assessed by eKare inSightTM),
6. Patient understands the nature of the procedure, is able to adhere to the protocol regimen, and provides a written informed consent prior to any study procedure.

Exclusion Criteria

1. Wound size decreased by > 20% after 1 week of standard-of-care-only period (screening period),
2. Patients with more than one leg ulcer , on the leg of the target wound, with an area greater than or equal to 2 cm2,
3. Signs of clinical infection of the wound or peri-wound, including purulent discharge, deep-tissue abscess, erysipelas, cellulitis, etc.,
4. Severely damaged skin (e.g. abrasion, erosion, exfoliation) extending >2 cm around the wound's edge,
5. Presence of gangrene, signs of systemic infection, sepsis, or osteomyelitis during screening phase,
6. Clinical suspicion of skin cancer (e.g., basal cell carcinoma (BCC), squamous cell carcinoma (SCC), melanoma, or sarcoma), near the target wound, which was not ruled out by biopsy,
7. Patients with skin disorders unrelated to the wound that are presented adjacent to the wound,
8. Patients suffering from chronic skin disorders (Idiopathic Pruritus, Psoriasis, Panniculitis, Pyoderma gangrenosum, etc.) that might deteriorate as a result of local trauma or debridement,
9. Wound has sinus tracts or tunnels extending under healthy tissue or penetrating into periosteum, fascia or bone,
10. Patients with primary lymphatic edema (Lymphedema),
11. A significant decrease in the arterial blood flow of the extremity ,
12. Known small vessels disease (PVD) of any etiology,
13. Patients with pre-enrolment wounds which are covered by eschar heavily saturated with iodine or by silver sulfadiazine (SSD) pseudoeschar (i.e. pseudoeschar as a result of SSD treatment),
14. History of allergy or atopic disease or a known sensitivity to pineapples, bromelain, papaya or papain, as well as known sensitivity to latex proteins (known as latex-fruit syndrome), bee venom or olive tree pollen,
15. Patients with poor nutritional status: albumin < 2.5g/dl, poorly controlled diabetes Mellitus (HbA1c > 12%), anemia (hemoglobin<8 g/dL), a leukocyte counts < 3,000/μl or >15000/μl, neutrophil count ≤1000/ μl, platelets <100,000/μl, abnormal liver function (AST, ALT>2 x upper limit of normal range), renal failure (Cr > 2.5 mg/dl and eGFR < 30ml/ min /1.73m2), BMI>48,
16. INR>2 or PTT > x 2 ULN (unless the patient receives coumarin derivatives anticoagulants (e.g. warfarin), and the INR and PTT levels are in their required levels and are stable),
17. Patients undergoing renal or peritoneal dialysis,
18. Any condition that would preclude safe participation in the study, e.g. significant or unstable cardiovascular, pulmonary, liver, hematological, immunological, neoplastic disease, active COVID-19, or any immediate life threatening condition,
19. Recent history or concurrent acute injury or disease that might compromise the patient's welfare, according to investigator discretion,
20. Patient is currently receiving, or has received at any time within three months prior to enrollment, or is planned to receive during trial period, any medications or treatments known to affect the wound healing processes; these include chronic systemic steroid intake with topical skin changes (i.e. thin, fragile skin with multiple heamatomas or previous laceration history) immuno-suppressive drugs, immunomodulating medications, chemotherapy and radiation therapy,
21. In case the subject is treated with Pentoxifylline, dosing is stable less than 4 weeks,
22. Mentally incompetent adults who are incapable of giving legal consent (e.g. dementia, psychiatric patients, etc.),
23. Concurrent use of non-approved drugs or alcohol abuse,
24. Pregnant women (positive pregnancy test) or nursing mothers,
25. Exposure to investigational intervention within three months prior to enrollment, or anticipated participation in another investigational drug trial or other intervention trial, while enrolled in the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
EscharEx (EX-03)	EscharEx (EX-03)	EX-03 is the code name of the third generation of EscharEx investigational medicinal product (IMP) formulation. A sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb ), the active pharmaceutical ingredient (API), that is blended with excipients. EX-03 5% powder, should be diluted with Water for Injection (WFI) prior usage.
Placebo	Placebo (Gel vehicle)	Placebo (Gel Vehicle, hydrogel) contains the same excipients as in EX-03, without the API. Placebo powder, should be diluted with Water for Injection (WFI) prior usage.

Primary Outcome Measures

Name	Time	Method
Incidence of complete debridement, clinically (visually) assessed after each application	up to 2 weeks	counting events of complete debridement
Incidence of complete wound closure	up to 12 weeks	counting events of complete wound closure

Secondary Outcome Measures

Name	Time	Method
Percent change in wound area, as assessed by eKare inSightTM	up to 12 weeks	count in percentage
Incidence of complete healthy viable granulation tissue, as assessed clinically	up to 2 weeks	counting events of complete granulation
Time to complete wound closure, clinically assessed	up to 12 weeks	count in days
Time to the first declaration of complete debridement, clinically assessed	up to 12 weeks	count in days

Trial Locations

Locations (5)

Limb Preservation Platform, Inc; 🇺🇸 Fresno, California, United States

Center for Clinical Research INC; 🇺🇸 San Francisco, California, United States

Northwell Health Comprehensive Wound Healing Center; 🇺🇸 Lake Success, New York, United States

University of Texas Health Science Center at San Antonio; 🇺🇸 San Antonio, Texas, United States

JPS Health Network/Acclaim Multispecialty Clinic; 🇺🇸 Fort Worth, Texas, United States